Cochrane · systematic review · CD013089
Radix Sophorae flavescentis versus no intervention or placebo for chronic hepatitis B
Liang, N, Kong, DZ, Ma, SS, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
4
No studies
3
Included studies
NR
No studies 3 · 42.9%Ungraded 0 · 0%Very low 4 · 57.1%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Radix Sophorae flavescentis versus no intervention or placebo for chronic hepatitis B
Population: chronic hepatitis B
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Radix Sophorae flavescentis vs no intervention or placebo | no estimate extracted | 1 study · 86 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Proportion of participants with 1 or more serious adverse events Radix Sophorae flavescentis vs no intervention or placebo | no estimate extracted | 10 studies · 1140 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Health‐related quality of life Radix Sophorae flavescentis vs no intervention or placebo | no estimate extracted | NR | No studies |
Hepatitis B‐related mortality Radix Sophorae flavescentis vs no intervention or placebo | no estimate extracted | NR | No studies |
Hepatitis B‐related morbidity Radix Sophorae flavescentis vs no intervention or placebo | no estimate extracted | NR | No studies |
Proportion of participants with 1 or more adverse events considered 'not to be serious' (at maximum Radix Sophorae flavescentis vs no intervention or placebo | RR 1.1 [0.76, 1.59] | 10 studies · 1050 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Surrogate outcomes: Proportion of participants with detectable HBV‐DNA (at maximum Radix Sophorae flavescentis vs no intervention or placebo | RR 0.61 [0.55, 0.68] | 29 studies · 2914 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |